Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Zhigen Pharmaceutical & Technology Co. Ltd. has 1 pending office action currently active. This matter is assigned to 1 distinct examiner, SAHIL CHANDER AGGARWAL, who is also the busiest examiner with 1 pending office action. The data reports 0 distinct art units for this portfolio, which may reflect a pending classification or a unique administrative status for the filing.
With 1 distinct examiner handling the 1 pending office action, the prosecution path is entirely dependent on the review of SAHIL CHANDER AGGARWAL. This creates a singular focus for the applicant's legal strategy. The current count of 0 distinct art units indicates that the application may be awaiting final assignment to a specific technical group within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843972 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | AGGARWAL, SAHIL CHANDER | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843972 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | AGGARWAL, SAHIL CHANDER | — | §101§103§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial